Myungmoon Pharm is simultaneously pursuing the efficiency of non-core assets and investment in core production facilities to improve its financial structure and expand its global business. The company is reducing earnings volatility from its golf course operations by switching to a lease and consignment model, while strengthening its high-value export base through the upgrade of its injectable production facilities.
According to industry sources, Myungmoon Pharm has shifted the operation of 'The Ban Golf Club,' owned by its subsidiary Myungmoon Investment Development, from direct management to a lease and consignment structure centered on a professional operator. The golf course operator has recently changed from Myungmoon Investment Development to 'Kakao VX,' marking the start of consignment operations.
This change is seen as a meaningful turning point for Myungmoon Pharm's financial stability and cash flow improvement, beyond a simple change in operator. Previously, the golf course business had high earnings volatility due to seasonality, fixed costs, and financial expenses. Although the subsidiary Myungmoon Investment Development recorded operating profits in recent years, financial costs burdened the consolidated earnings.
Myungmoon Pharm expects to save tens of billions of Korean won annually in financial costs through rental income from the professional operator. The reduction in labor and maintenance costs from direct operation is also expected to stabilize the overall cash generation structure.
This restructuring is seen as a strategy to improve the profitability of non-core assets and reallocate financial capacity to the core business. The cash flow secured from the efficient golf course operations can serve as a foundation for increasing investment capacity in core businesses.
At the same time, Myungmoon Pharm is accelerating investment in its injectable business, a key growth driver. The company was recently selected for a national project led by the Korea Health Industry Development Institute (KHIDI) called 'Injectable Production Facility Expansion and EU GMP Certification Support Project.' This project supports the construction of sterile injectable production facilities meeting global standards and securing EU GMP certification, the European pharmaceutical manufacturing and quality control standard.
Myungmoon Pharm plans to invest approximately 20 billion Korean won in production facility upgrades with government support. The goal is to establish an advanced, automated production system early.
Currently, Myungmoon Pharm exports 21 injectable products to 29 countries. However, due to production capacity limitations, it is reportedly supplying only half of actual demand.
The company aims to expand into highly regulated advanced markets such as Europe, Australia, and Canada through production facility expansion and EU GMP certification. These advanced markets offer higher drug prices and profitability compared to existing Southeast Asian and Latin American markets, which is expected to improve profit margins beyond simple sales growth. Myungmoon Pharm has set a mid- to long-term target of expanding injectable export volume to over 10 billion Korean won.
The market is paying attention to Myungmoon Pharm's strategy of reducing the burden of non-core businesses while linking secured financial stability to investment in high-value production facilities. Analysts suggest that if the virtuous cycle of improving cost structure through efficient golf course operations and then expanding global certification and production capacity materializes, the company's business transformation could accelerate.
A pharmaceutical industry insider commented, "In the past, the golf course business contributed to consolidated earnings volatility, but after the operational restructuring, stable rental income and financial cost savings are expected. If the expansion into global markets based on EU GMP is realized, Myungmoon Pharm's mid- to long-term growth potential could be evaluated differently."
Source: Read the original report | Published: May 26, 2026